1887

Abstract

Previous results in the laboratory of the authors showed that strain 905, isolated during ‘cachaça’ production, was able to colonize and survive in the gastrointestinal tract of germ-free and conventional mice, and to protect these animals against oral challenge with serotype Typhimurium or . In the present work, the effects of 905 on the translocation of . Typhimurium (mesenteric lymph nodes, Peyer's patches, spleen, liver) as well as on the immune system (number of Küpffer cells, immunoglobulin production, clearance of B) were evaluated in gnotobiotic and/or conventional mice. The treatment with the yeast reduced significantly the translocation of . Typhimurium to liver in gnotobiotic animals and to all the organs tested in conventional mice. The number of Küpffer cells per 100 hepatocytes in liver was significantly higher (<0.05) in yeast mono-associated mice (52.9±15.7) than in germ-free controls (38.1±9.0). Probably as a consequence, clearance of B from the bloodstream was more efficient in yeast mono-associated animals when compared to germ-free mice. Higher levels (<0.05) of secretory IgA in intestinal content and of IgA and IgM in serum were observed in yeast mono-associated mice when compared to germ-free group. Concluding, the protection against pathogenic bacteria observed in a previous study was probably due to a modulation of both local and systemic immunity of mice treated with 905.

Keyword(s): sIgA, secretory IgA
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.46525-0
2007-03-01
2021-02-25
Loading full text...

Full text loading...

/deliver/fulltext/jmm/56/3/352.html?itemId=/content/journal/jmm/10.1099/jmm.0.46525-0&mimeType=html&fmt=ahah

References

  1. Bartlett J. G. 1992; Antibiotic-associated diarrhea. Clin Infect Dis 15:573–581 [CrossRef]
    [Google Scholar]
  2. Berg R. D. 1995; Bacterial translocation from the gastrointestinal tract. Trends Microbiol 3:149–154 [CrossRef]
    [Google Scholar]
  3. Berg R. D. 1996; The indigenous gastrointestinal microflora. Trends Microbiol 4:430–435 [CrossRef]
    [Google Scholar]
  4. Born P., Lersch C., Zimmerhackl B., Claassen M. 1993; The Saccharomyces boulardii therapy of HIV-associated diarrhea. Dtsch Med Wochenschr 118:765
    [Google Scholar]
  5. Brandão R. L., Castro I. M., Bambirra E. A., Amaral S. C., Fietto L. G., Tropia M. J. M., Neves M. J., Dos Santos R. G., Gomes N. C. M., Nicoli J. R. 1998; Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevisiae . Appl Environ Microbiol 64:564–568
    [Google Scholar]
  6. Buts J. P., Bernasconi P., Vaerman J. P., Dive C. 1990; Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii . Dig Dis Sci 35:251–256 [CrossRef]
    [Google Scholar]
  7. Castagliuolo I., Riegler M. F., Valenick L., Lamont J. T., Pothoulakis C. 1999; Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 67:302–307
    [Google Scholar]
  8. Chiva M., Soriano G., Rochat I., Peralta C., Rochat F., Llovet T., Mirelis B., Schiffrin E. J., Guarner C., Balanzo J. 2002; Effect of Lactobacillus johnsonii La1 and antioxidants on intestinal flora and bacterial translocation in rats with experimental cirrhosis. J Hepatol 37:456–462 [CrossRef]
    [Google Scholar]
  9. Ciriello C. J., Lachance M. A. 2001 yeastcompare University of Western Ontario; London, ON, Canada:
    [Google Scholar]
  10. Czerucka D., Rampal P. 2002; Experimental effects of Saccharomyces boulardii on diarrheal pathogens. Microbes Infect 4:733–739 [CrossRef]
    [Google Scholar]
  11. Czerucka D., Roux I., Rampal P. 1994; Saccharomyces boulardii inhibits secretagogue-mediated adenosine 3′,5′-cyclic monophosphate induction in intestinal cells. Gastroenterology 106:65–72
    [Google Scholar]
  12. Czerucka D., Dahan S., Mograbi B., Rossi B., Rampal P. 2000; Saccharomyces boulardii preserves the barrier function and modulates the transduction pathway induced in enteropathogenic Escherichia coli -infected T84 cells. Infect Immun 68:5998–6004 [CrossRef]
    [Google Scholar]
  13. Dahan S., Dalmasso G., Imbert V., Peyron J.-F., Rampal P., Czerucka D. 2003; Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli -induced signaling pathways in T84 cells. Infect Immun 71:766–773 [CrossRef]
    [Google Scholar]
  14. Elmer G. W., McFarland L. V., Surawicz C. M., Danko L., Greenberg R. N. 1999; Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment Pharmacol Ther 13:1663–1668 [CrossRef]
    [Google Scholar]
  15. Fietto J. L. R., Araújo R. S., Valadão F. N., Fietto L. G., Brandão R. L., Neves M. J., Gomes C. O., Nicoli J. R., Castro I. M. 2004; Molecular and physiological comparisons between Saccharomyces cerevisiae and Saccharomyces boulardii . Can J Microbiol 50:615–621 [CrossRef]
    [Google Scholar]
  16. Food and Agriculture Organization of the United Nations & World Health Organization 2002; Guidelines for the Evaluation of Probiotics in Food , Food and Agriculture Organization of the United Nations and World Health Organization Working Group Report. London, Ontario, Canada: April 30–May 1 2002
  17. Gregory S. H., Sagnimeni A. J., Wing E. J. 1996; Bacteria in the bloodstream are trapped in the liver and killed by immigrating neutrophils. J Immunol 157:2514–2520
    [Google Scholar]
  18. Gedek B. R. 1999; Adherence of Escherichia coli serogroup O157 and the Salmonella typhimurium mutant DT 104 to the surface of Saccharomyces boulardii . Mycoses 42:261–264 [CrossRef]
    [Google Scholar]
  19. Gun F., Salman T., Gurler N., Olgac V. 2005; Effect of probiotic supplementation on bacterial translocation in thermal injury. Surg Today 35:760–764 [CrossRef]
    [Google Scholar]
  20. Hajishengallis G., Nikolova E., Russel M. W. 1992; Inhibition of Streptococcus mutans adherence to saliva-coated hydroxyapatite by human secretory immunoglobulin A antibodies to the cell surface protein antigen I/II: reversal by IgA 1 protease cleavage. Infect Immun 60:5057–5064
    [Google Scholar]
  21. Hamuro J., Akiyama Y., Iguchi Y., Isawa M., Matsuo T. 1982; Distinct roles of serum factors induced by a T cell specific immune adjuvant lentinan in cellular immune responses. Int J Immunopharmacol 4:268
    [Google Scholar]
  22. Herek O., Kara I. G., Kaleli I. 2004; Effects of antibiotics and Saccharomyces boulardii on bacterial translocation in burn injury. Surg Today 34:256–260 [CrossRef]
    [Google Scholar]
  23. Hirakata Y., Tomono K., Tateda K., Matsumoto T., Furuya N., Shimoguchi K., Kaku M., Yamaguchi K. 1991; Role of bacterial association with Küpffer cells in occurrence of endogenous systemic bacteremia. Infect Immun 59:289–294
    [Google Scholar]
  24. Jahn H. U., Ullrich R., Schneider T., Liehr R. M., Schieferdecker H. L., Holst H., Zeitz M. 1996; Immunological and trophical effects of Saccharomyces boulardii on the small intestine in healthy human volunteers. Digestion 57:95–104 [CrossRef]
    [Google Scholar]
  25. Jones B. D., Falkow S. 1996; Salmonellosis: host immune responses and bacterial virulence determinants. Annu Rev Immunol 14:533–561 [CrossRef]
    [Google Scholar]
  26. Kovacs D. J., Berk T. 2000; Recurrent Clostridium difficile -associated diarrhea and colitis treated with Saccharomyces cerevisiae (baker's yeast) in combination with antibiotic therapy: a case report. J Am Board Farm Pract 13:138–140 [CrossRef]
    [Google Scholar]
  27. Kumura H., Tanoue Y., Tsukahara M., Tanaka T., Shimazaki K. 2004; Screening of dairy yeast strains for probiotic applications. J Dairy Sci 87:4050–4056 [CrossRef]
    [Google Scholar]
  28. Martins F. S., Nardi R. M. D., Arantes R. M. E., Rosa C. A., Neves M. J., Nicoli J. R. 2005; Screening of yeast as probiotic based on capacities to colonize the gastrointestinal tract and to protect against enteropathogen challenge in mice. J Gen Appl Microbiol 51:83–92 [CrossRef]
    [Google Scholar]
  29. McFarland L. V., Bernasconi P. 1993; Saccharomyces boulardii : a review of an innovative biotherapeutic agent. Microb Ecol Health Dis 6:157–171 [CrossRef]
    [Google Scholar]
  30. McFarland L. V., Surawicz C. M., Greenberg R. N., Elmer G. W., Moyer K. A., Melcher S. A., Bowen K. E., Cox J. L. 1995; Prevention of β -lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 90:439–448
    [Google Scholar]
  31. Moreau M. C., Raibaud P., Muller M. C. 1982; Relation entre le développement du systéme immunitaire intestinal à IgA et l'établissement de la flore microbienne dans le tube digestif de souris holoxênique. Ann Inst Pasteur Immunol 133B:29–39
    [Google Scholar]
  32. Moura L. N., Neumann E., Vieira L. Q., Nicoli J. R. 2001; Protection by Lactobacillus acidophilus UFV-H2B20 against experimental oral infection with Salmonella enterica subsp. enterica ser. Typhimurium in gnotobiotic and conventional mice. Br J Microbiol 32:66–69 [CrossRef]
    [Google Scholar]
  33. National Research Council. 1996 Guide for the Care and Use of Laboratory Animals Washington, DC: National Academy Press;
    [Google Scholar]
  34. Neumann E., Oliveira M. A. P., Cabral C. M., Moura L. N., Nicoli J. R., Vieira E. C., Cara D. C., Podoprigora G. I., Vieira L. Q. 1998; Monoassociation with Lactobacillus acidophilus UFV-H2B20 stimulates the phagocytic system of germ-free mice. Br J Med Biol Res 31:1565–1573 [CrossRef]
    [Google Scholar]
  35. Neves M. J., Etchebehere L., Brandão R. L., Castro I. M., Lima M. E., Nicoli J. R. 2002; Partial characterization of cholera toxin binding on membranes of Saccharomyces boulardii . Microecol Ther 29:185–190
    [Google Scholar]
  36. Patchen M., McVittie T. 1982; Effects of a soluble glucan on hemopoietic stem cell proliferation. Int J Immunopharmacol 4:273
    [Google Scholar]
  37. Pleasants J. R. 1974; Gnotobiotics. In Handbook of Laboratory Animal Science p  119–174 Edited by Melby E. C. Jr, Altmann N. H. Cleveland: CRC Press;
    [Google Scholar]
  38. Peret L. A., Penna F. J., Bambirra E. A., Nicoli J. R. 1998; Dose effect of oral Saccharomyces boulardii treatments on morbidity and mortality in immunosuppressed mice. J Med Microbiol 47:111–116 [CrossRef]
    [Google Scholar]
  39. Pothoulakis C., Kelly C. P., Joshi M. A., Gao N., O'Keane C. J., Castagliuolo I., Lamont J. T. 1993; Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 104:1108–1115
    [Google Scholar]
  40. Qamar A., Aboudola S., Warny M., Michetti P., Pothoulakis C., Lamont J. T., Kelly C. P. 2001; Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun 69:2762–2765 [CrossRef]
    [Google Scholar]
  41. Rodrigues A. C., Nardi R. M., Bambirra E. A., Vieira E. C., Nicoli J. R. 1996; Effect of Saccharomyces boulardii against experimental oral infection with Salmonella typhimurium and Shigella flexneri in conventional and gnotobiotic mice. J Appl Bacteriol 81:251–256 [CrossRef]
    [Google Scholar]
  42. Rodrigues A. C., Cara D. C., Fretez S. H. G. G., Cunha F. Q., Vieira E. C., Nicoli J. R., Vieira L. Q. 2000; Saccharomyces boulardii stimulates sIgA production and the phagocytic system of gnotobiotic mice. J Appl Microbiol 89:404–414 [CrossRef]
    [Google Scholar]
  43. Saba T. M. 1970; Physiology and physiopathology of the reticuloendothelial system. Arch Intern Med 126:1031–1052 [CrossRef]
    [Google Scholar]
  44. Scarpignato C., Rampal P. 1995; Prevention and treatment of traveler's diarrhea: a clinical pharmacological approach. Chemotherapy 41:48–81 [CrossRef]
    [Google Scholar]
  45. Silva A. M., Barbosa F. H. F., Duarte R., Vieira L. Q., Arantes R. M. E., Nicoli J. R. 2004; Effect of Bifidobacterium longum ingestion on experimental salmonellosis in mice. J Appl Microbiol 97:29–37 [CrossRef]
    [Google Scholar]
  46. Surawicz C. M. 2003; Probiotics, antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in humans. Best Pract Res Clin Gastroenterol 17:775–783 [CrossRef]
    [Google Scholar]
  47. Surawicz C. M., McFarland L. V., Greenberg R. N., Rubin M., Fekety R., Mulligan M. E., Garcia R. J., Brandmarker S., Bowen K. other authors 2000; The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii . Clin Infect Dis 31:1012–1017 [CrossRef]
    [Google Scholar]
  48. Van der Aa Kühle A., Skovgaard K., Jespersen L. 2005; In vitro screening of probiotic properties of Saccharomyces cerevisiae var. boulardii and food-borne Saccharomyces cerevisiae strains. Int J Food Microbiol 101:29–39 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.46525-0
Loading
/content/journal/jmm/10.1099/jmm.0.46525-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error